Recombinant human interferon α2b biosimilar (Harbin High-Tech White Swan Pharmaceutical)

重组人干扰素α2b生物类似药（哈高科白天鹅）

Report date: 2022/01/14 13:23:58

Base Information

Drug NameRecombinant human interferon α2b biosimilar (Harbin High-Tech White Swan Pharmaceutical)
Drug Alias NameRecombinant human interferon A2b biosimilar重组人干扰素α2b生物仿制药（哈高科白天鹅）recombinant human interferon alfa-2b follow-on biologicFu Li Sheng
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokinesBiologics > Biosimilar
Mechanisms of ActionInterferon-alpha/beta receptor alpha chain stimulants
TargetsInterferon-alpha/beta receptor alpha chain
Therapy Area/IndicationsHepatitisMultiple MyelomaLymphoma, Non-Hodgkin +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesHarbin High-Tech Group Baitian'Er Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesHarbin High-Tech Group Baitian'Er Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsHepatitisMultiple MyelomaLymphoma, Non-Hodgkin +[7] 
Inactive IndicationsN/A

Other Information

ATC CodeL03AB05
Related LinksN/A